Wilson D J, Wallin J D, Vlachakis N D, Freis E D, Vidt D G, Michelson E L, Langford H G, Flamenbaum W, Poland M P
Am J Med. 1983 Oct 17;75(4A):95-102. doi: 10.1016/0002-9343(83)90141-9.
The antihypertensive effects of intravenous labetalol were evaluated in 59 patients with hypertensive crises or severe hypertension in need of rapid lowering of blood pressure in a multicenter study. Patients appearing with a supine diastolic blood pressure 125 mm Hg or greater, or a supine systolic blood pressure of more than 200 mm Hg received an initial mini-bolus injection (20 mg) of labetalol. This was followed by repeated incremental doses of 20 to 80 mg given at 10 minute intervals to achieve a supine diastolic blood pressure of less than 95 mm Hg or decrease 30 mm Hg or greater, or a satisfactory decrease in systolic blood pressure. Patients were stratified into those who had taken antihypertensive medication within 24 hours and those who had not. The initial mini-bolus injection caused rapid but not abrupt reduction in blood pressure; the baseline mean blood pressure decreased 23/14 mm Hg. Further injections were needed in the majority of patients (mean: 197 mg). The blood pressure reduction after the last dose of labetalol was 55/33 mm Hg. In pretreated patients and in those who had no medication for 24 hours prior to the intravenous labetalol, the response was similar. Heart rate decreased 10 beats per minute in the total population. In patients pretreated with beta-adrenergic blockers, blood pressure response was similar to that in the total group (59/35 versus 55/33 mm Hg), but heart rate remained essentially unchanged. The dose required to achieve the therapeutic effect was less in pretreated patients than in untreated patients, but the duration of action was shorter. No serious adverse effects were encountered even in patients with concomitant diagnoses of acute left ventricular failure, myocardial infarction, stable congestive heart failure, atrial fibrillation, angina pectoris, acute stroke, transient ischemic attack or encephalopathy. Labetalol is a safe and effective treatment for a rapid blood pressure reduction in hypertensive emergencies.
在一项多中心研究中,对59例患有高血压危象或严重高血压且需要迅速降低血压的患者评估了静脉注射拉贝洛尔的降压效果。仰卧位舒张压125mmHg或更高,或仰卧位收缩压超过200mmHg的患者接受了初始小剂量注射(20mg)拉贝洛尔。随后每隔10分钟重复递增剂量注射20至80mg,以达到仰卧位舒张压低于95mmHg或降低30mmHg或更多,或使收缩压有满意的下降。患者被分为在24小时内服用过抗高血压药物的患者和未服用过的患者。初始小剂量注射导致血压迅速但非突然下降;基线平均血压下降了23/14mmHg。大多数患者(平均:197mg)需要进一步注射。最后一剂拉贝洛尔后的血压下降为55/33mmHg。在接受过预处理的患者和在静脉注射拉贝洛尔前24小时未服用药物的患者中,反应相似。总体人群中心率每分钟下降10次。在用β-肾上腺素能阻滞剂预处理的患者中,血压反应与整个组相似(59/35对55/33mmHg),但心率基本保持不变。达到治疗效果所需的剂量在预处理患者中比未治疗患者少,但作用持续时间较短。即使在同时诊断为急性左心室衰竭、心肌梗死、稳定的充血性心力衰竭、心房颤动、心绞痛、急性中风、短暂性脑缺血发作或脑病的患者中也未遇到严重不良反应。拉贝洛尔是一种用于高血压急症中快速降低血压的安全有效的治疗方法。